Negative in Ames and in vivo micronucleus; positive in vitro micronucleus (24-hour); overall non-genotoxic
“Oveporexton was found to be negative in an Ames assay and in an in vivo micronucleus assay; however, it was found to be positive for induction of micronuclei in an in vitro micronucleus assay following 24-hours of continuous treatment. Overall oveporexton was determined to be non-genotoxic.”
✓ VerifiedFDA multi-discipline review, p. 48Source ↗
Carcinogenicity
2-year rat and 6-month transgenic mouse: not carcinogenic
“Oveporexton was also found to be non-carcinogenic in a GLP 2-year rat and a GLP 6-month transgenic mouse carcinogenicity study.”
✓ VerifiedFDA multi-discipline review, p. 48Source ↗
Instead of carcinogenicity
Not stated in public reviews
Not reported in the public reviews. Reviewers summarise selectively, so this usually means it wasn't discussed publicly, not that it wasn't studied.
Instead of genotoxicity
Not stated in public reviews
Not reported in the public reviews. Reviewers summarise selectively, so this usually means it wasn't discussed publicly, not that it wasn't studied.
DRG histopathology
Not stated in public reviews
Not reported in the public reviews. Reviewers summarise selectively, so this usually means it wasn't discussed publicly, not that it wasn't studied.
Reproductive & developmental
Rat and rabbit EFD: no drug-related malformations or embryo-fetal lethality
“There were no drug-related effects on the incidence of congenital malformations or embryo-fetal lethality in either rats or rabbits.”
✓ VerifiedFDA multi-discipline review, p. 48Source ↗
Safety pharmacology
Rats: CNS (body temperature changes, hyperactivity at ≥20 mg/kg) and respiratory effects; monkeys: increased blood pressure and LV pressure at ≥3 mg/kg
“Results from GLP-compliant safety pharmacology studies indicated that oveporexton can affect the CNS (increased body temperature at 20 and 100 mg/kg, decreased body temperature at 1000 mg/kg, and hyperactivity at ≥20 mg/kg in rats), the cardiovascular system (increased blood pressure and left ventricular pressure at ≥3 mg/kg in monkeys), and the respiratory system”
✓ VerifiedFDA multi-discipline review, p. 46Source ↗
Genotox: Ames
Negative
“Oveporexton was found to be negative in an Ames assay and in an in vivo micronucleus assay; however, it was found to be positive for induction of micronuclei in an in vitro micronucleus assay following 24-hours of continuous treatment.”
✓ VerifiedFDA multi-discipline review, p. 48Source ↗
Genotox: in vitro mammalian
In vitro micronucleus: positive after 24-hour continuous treatment; overall judged non-genotoxic
“Oveporexton was found to be negative in an Ames assay and in an in vivo micronucleus assay; however, it was found to be positive for induction of micronuclei in an in vitro micronucleus assay following 24-hours of continuous treatment. Overall oveporexton was determined to be non-genotoxic.”
✓ VerifiedFDA multi-discipline review, p. 48Source ↗
Genotox: in vivo
In vivo micronucleus: negative
“Oveporexton was found to be negative in an Ames assay and in an in vivo micronucleus assay; however, it was found to be positive for induction of micronuclei in an in vitro micronucleus assay following 24-hours of continuous treatment.”
✓ VerifiedFDA multi-discipline review, p. 48Source ↗
Carcinogenicity model
2-year rat; 26-week Tg-rasH2 mouse; both negative
“Refer to section 5.5.4 for a summary of the negative GLP-compliant carcinogenicity studies of oveporexton: a 26-week carcinogenicity study in transgenic hemizygous mice (Tg-rasH2 mice) and a 2-year carcinogenicity study in rats.”
✓ VerifiedFDA multi-discipline review, p. 300Source ↗
Carcinogenicity timing
2-year rat and 6-month transgenic mouse carcinogenicity studies completed and reviewed with the NDA
“Oveporexton was also found to be non-carcinogenic in a GLP 2-year rat and a GLP 6-month transgenic mouse carcinogenicity study.”
✓ VerifiedFDA multi-discipline review, p. 48Source ↗
hERG / QT
hERG IC50 >3 µg/mL, >3000-fold human unbound Cmax at MRHD
“The IC50 value for hERG inhibition was >3 μg/mL, which provides an approximate safety margin of >3000-fold compared with the human Cmax,ss,unbound (0.98 ng/mL) at the MRHD (Study No.B240294).”
✓ VerifiedFDA multi-discipline review, p. 54Source ↗
Not genotoxic overall: Ames negative; in vitro chromosome aberration positive without (not with) metabolic activation; rat micronucleus and comet negative